Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25020373 | 0.87 | CASP3 (0.32) | L3MBTL1TSHRALDH1A1CASP3HTT | |
| SCHEMBL23218005 | 0.79 | CASP3 (0.32) | L3MBTL1TSHRALDH1A1CASP3HTT | |
| SCHEMBL31172125 | 0.77 | CASP3 (0.33) | L3MBTL1TSHRALDH1A1CASP3HTT | |
| SCHEMBL22636487 | 0.77 | CASP3 (0.33) | L3MBTL1TSHRALDH1A1CASP3HTT | |
| SCHEMBL23698705 | 0.75 | ALDH1A1 (0.35) | L3MBTL1LMNACYP1A2TSHRCYP2C19 | |
| SCHEMBL24604442 | 0.73 | RAB9A (0.36) | L3MBTL1LMNACYP1A2TSHRCYP2C19 | |
| SCHEMBL7736866 | 0.72 | CASP3 (0.32) | L3MBTL1TSHRSMN1; SMN2ALDH1A1CASP3 | |
| SCHEMBL17485426 | 0.72 | NPC1 (0.35) | L3MBTL1LMNACYP1A2TSHRCYP2C19 | |
| SCHEMBL23084629 | 0.70 | CHRM2 (0.34) | L3MBTL1LMNACYP1A2TSHRCYP2C19 | |
| SCHEMBL26024103 | 0.69 | HTT (0.35) | L3MBTL1LMNACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | GRM5 916/4885L3MBTL1 4777/4885LMNA 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.